Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Comparative risks and benefits of drugs. Methodological problems].

M Biscos-Garreau¹, M Girard

¹Groupe de Recherche en Pharmacovigilance, Neauphle-le-Château.

|September 1, 1988

Summary

Focalizing toxicities, like antidepressant hematotoxicity, bias drug safety assessments. Validating safety data globally and comparatively is crucial for accurate risk-benefit analysis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Complete nucleotide sequence of the genomic RNA of a French isolate of Pepino mosaic virus (PepMV). Brief report.

Archives of virology·2002

Same author

The influence of long emersion on biota, ammonium fluxes and nitrification in intertidal sediments of Marennes-Oléron Bay, France.

Marine environmental research·2002

Same author

Investing in CAD/CAM.

Journal of dental technology : the peer-reviewed publication of the National Association of Dental Laboratories·2002

Same author

Inositol hexakisphosphate-mediated regulation of glutamate receptors in rat brain sections.

Hippocampus·2002

Same author

Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10.

Human molecular genetics·2001

Same author

DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques.

Developments in biologicals·2001

Area of Science:

Pharmacology
Drug Safety Evaluation
Clinical Toxicology

Background:

A focalizing toxicity disproportionately captures attention in drug safety evaluations.
Hematotoxicity associated with second-generation antidepressants serves as a prime example.
Biased perception and reporting of such toxicities impede objective risk-benefit assessments.

Purpose of the Study:

To define focalizing toxicity and its impact on drug safety perception.
To outline principles and methodologies for validating drug safety data.
To emphasize the necessity of a global and comparative approach to drug risk-benefit assessment.

Main Methods:

Conceptual framework development for defining focalizing toxicity.
Analysis of safety data handling and reporting biases.
Case examples using antidepressant-associated hematotoxicity to illustrate validation principles.

Main Results:

Focalizing toxicities can skew the perception of a drug's overall safety profile.
Standardized validation of safety data is essential to mitigate bias.
Antidepressant safety data highlights challenges in risk-benefit evaluation.

Conclusions:

Drug safety assessment requires a comprehensive and unbiased approach.
The concept of focalizing toxicity underscores the need for rigorous data validation.
Global and comparative analysis is paramount for accurate drug risk-benefit determination.

Related Experiment Videos